of statistical graphics and elimination of redundant work processes. From discovery, pre-clinical and clinical trials, through marketing and epidemiology, iCG enables scientific data to be presented as actionable information in...
Myriad Stops Work on Alzheimer's Drug |Published: June 30, 2008 9:50 AM By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Myriad Genetics Inc. (MYGN) is discontinuing development of its lead drug candidate,...
SALT LAKE CITY—Myriad Genetics Inc. announced in late May it entered into a European commercialization agreement with Denmark-based H. Lundbeck A/S for European commercialization of Flurizan, Myriad’s lead therapeutic candidate...
Parkinson's disease progression slows down in phase III clinical study of ADAGIO that used Azilect 1mg tablets. Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the...
